Catheter Precision (NYSEAMERICAN:VTAK) Issues Quarterly Earnings Results

Catheter Precision (NYSEAMERICAN:VTAK – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($8.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($13.30) by $5.14, FiscalAI reports. The business had revenue of $1.84 million for the quarter, compared to analyst estimates of $2.80 million. Catheter Precision had a negative net margin of 656.03% and a negative return on equity of 37.53%.

Catheter Precision Stock Performance

Shares of NYSEAMERICAN:VTAK remained flat at $0.15 during midday trading on Monday. The firm has a market cap of $2.17 million, a price-to-earnings ratio of -0.02 and a beta of -0.99. The firm has a 50-day moving average of $0.73 and a 200-day moving average of $7.35. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.18 and a current ratio of 0.19. Catheter Precision has a 1 year low of $0.13 and a 1 year high of $3.20.

About Catheter Precision

(Get Free Report)

Catheter Precision, Inc. is a medical device company focused on developing technologies for cardiac electrophysiology, a field involving the diagnosis and treatment of heart-rhythm disorders. Its products are designed to support physicians during procedures used to evaluate and treat cardiac arrhythmias, including ventricular tachycardia and other irregular heart rhythms. The company’s product portfolio includes the VIVO system, a noninvasive 3D cardiac mapping and navigation platform intended to help clinicians identify the origin of ventricular arrhythmias and plan catheter-ablation procedures.

Read More

Earnings History for Catheter Precision (NYSEAMERICAN:VTAK)

Receive News & Ratings for Catheter Precision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catheter Precision and related companies with MarketBeat.com's FREE daily email newsletter.